Investigational topical anticholinergics in clinical development for the treatment of hyperhidrosis

  title={Investigational topical anticholinergics in clinical development for the treatment of hyperhidrosis},
  author={Stamatios Gregoriou and Anna Campanati and Dimitrios Rigopoulos and Alexandros Stratigos and George Kontochristoulos},
  journal={Expert Opinion on Investigational Drugs},
  pages={479 - 482}
Focal hyperhidrosis has an incidence of up to 4.8%. % [1]. Abnormal sympathetic hyperactivity is the best documented component of its pathogenesis.Management of focal hyperhidrosis includes aluminu... 
3 Citations
Sofpironium bromide: an investigational agent for the treatment of axillary hyperhidrosis
An overview of pharmaceutical characteristics, efficacy and safety data from phase II and III clinical trials on sofpironium bromide (SB), a topical anticholinergic agent that has been employed for the treatment of PAH and has already received its first approval in Japan in the form of 5% gel formulation.
The pharmacological treatment and management of hyperhidrosis
The authors report on, in this narrative review, the emerging data from the literature focusing on the pharmacological treatments to draw up a drug treatment flow chart for patients with idiopathic hyperhidrosis, taking into consideration specific differences among axillary, palmoplantar, and craniofacialhyperhidrosis.
Synthetic Approaches to the New Drugs Approved During 2020.
This Review is part of a continuing series presenting the most likely process-scale synthetic approaches to 44 new chemical entities approved for the first time anywhere in the world during 2020.


Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults
Evaluated the efficacy and tolerability of oxybutynin 3% gel in adolescents and young adults with primary focal hyperhidrosis and found it to be safe and effective.
Topical glycopyrrolate reduces axillary hyperhidrosis
  • D. Baker
  • Medicine
    Journal of the European Academy of Dermatology and Venereology : JEADV
  • 2016
The initial effectiveness of 1% and 2% topical glycopyrrolate spray is determined and this is compared with Botulinum toxin type A injections for the management of axillary hyperhidrosis.
Topical Treatment of Primary Focal Hyperhidrosis, Part 2.
  • E. Zur
  • Medicine
    International journal of pharmaceutical compounding
  • 2019
This represents part 2 of a 2-part article on the topic of primary focal hyperhidrosis that provides a comprehensive review of the active pharmaceutical ingredients glycopyrronium salts and oxybutynin chloride in the treatment ofPrimary focalhyperhidrosis.
Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double‐blinded, placebo‐controlled, split‐face study
  • M. Y. Hyun, I. Son, C. Hong
  • Medicine, Psychology
    Journal of the European Academy of Dermatology and Venereology : JEADV
  • 2015
Although facial hyperhidrosis has been frequently associated with a diminished quality of life, various conservative modalities for its management are still far from satisfactory.
A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial
1% GPB cream may provide an effective new treatment option exhibiting a good safety profile for patients with primary axillary hyperhidrosis.
A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis
Umeclidinium (UMEC) is a long‐acting muscarinic antagonist (LAMA) developed as a dermal formulation that can be used as a treatment for hyperhidrosis.
Management Strategies Of Palmar Hyperhidrosis: Challenges And Solutions
This review will provide an update on current and emerging concepts of management for excessive hand sweating to help clinicians optimize therapeutic decision-making.
Safety and efficacy of topical formulations containing 0·5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double‐blind, placebo‐controlled study
The objective of this study was to assess safety and tolerability, efficacy and pharmacokinetics, of escalating concentrations of glycopyrronium bromide (GPB), a competitive antagonist of muscarinic acetylcholine receptor mAChR, in subjects with axillary hyperhidrosis.
Topical Oxybutynin 10% Gel for the Treatment of Primary Focal Hyperhidrosis: A Randomized Double-blind Placebo-controlled Split Area Study.
Twice-daily topical application of oxybutynin 10% gel appears to be an effective, safe and well-tolerated treatment for focal primary hyperhidrosis.